Clinical Trials Logo

Kidney Transplantation clinical trials

View clinical trials related to Kidney Transplantation.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06445205 Recruiting - Clinical trials for Kidney Transplant Rejection

Utilising Volumetric Absorptive Microsampling (VAMS) Technology to Monitor Tacrolimus and Creatinine

Start date: February 13, 2024
Phase:
Study type: Observational

Tacrolimus is a medicine given to try and stop rejection of a new kidney after transplant surgery. If too much taken the kidney may be damaged. If not enough taken, the risk of rejection is increased. Creatinine is a waste product made by the muscles and is normally removed from the body by the kidneys. If kidney function gets worse, the creatinine level in the blood goes up and means the new new kidney is not working properly. It is important to monitor levels of tacrolimus and creatinine regularly, to keep the kidney as healthy as possible. Regular monitoring also aids with balancing the amount of tacrolimus that patients need to take. The COVID-19 pandemic led to changes in the delivery of transplant services. One such changes was a move to the use of point-of-care, and at home devices. The study involves the set-up a new method in an NHS laboratory to test tacrolimus and creatinine levels in blood collected in the normal blood tubes and to compare the results with this new collection device, to see if the results are the same. If the results match, patients will continue to collect a blood sample using the new devices and send it to the laboratory. This will save both patients and the NHS time and money as they will not have to travel to a hospital to have their bloods taken.

NCT ID: NCT06440330 Recruiting - Clinical trials for Kidney Transplant; Complications

Define Predictors for Posttransplant Diabetes Mellitus Study

DECODE
Start date: September 1, 2023
Phase:
Study type: Observational

The primary aim of this prospective, multicentre study is to develop an accurate and convenient tool to predict the risk of PTDM at 3 months post-transplant, based on information on the day of transplantation (day 0). In order to create such model, we will start by identifying individual predictor variables at the day of transplantation and subsequently explore the optimal combination of these predictors in multivariable models. Secondary objectives include: - Compare the performance of the model based on predictor variables at day 0 with existing models for prediction of PTDM (Chakkera, San Antonio Diabetes Prediction Model and Framingham Offspring Study Diabetes Mellitus algorithm) - Explore the glucose level evolution during the first 2 weeks after transplantation using continuous glucose monitoring, and its relationship with baseline patient characteristics and immunosuppressant drug use. - Evaluate the added value of incorporating information on glucose levels in the first and second weeks post-transplant to improve the PTDM prediction model. - Identify predictors for early post-transplant hyperglycemia (first 2 weeks post-transplantation) - Explore the correlation between early post-transplant hyperglycemia (fasting glycemia, pre-dinner glycemia) and PTDM at 3 months

NCT ID: NCT06379009 Recruiting - Frailty Clinical Trials

Effect of Home-based Training Program for Kidney Transplant Recipients (HOMETRAIN-KTR)

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

Does home-based training work in kidney transplant recipients with reduced physical function? The goal of this clinical trial is to learn if home-based training works to better physical function in adult kidney transplant recipients. It will also learn about participants preoperative physical function. The main question it aim to answer is - Does home-based training improves physical function in kidney transplant recipients. - All the participants are assessed to have reduced physical function before the transplantation Participants will: - follow either a home-based training program or todays standard of physical activity after kidney transplantation - the program starts 4 weeks after the transplantation and lasts for 12 weeks. A physiotherapist will help the participants in the beginning. - the program consists of both cardio-training, strength-straining and optional activity - the training group will be followed up every week by phone. Their activity will be documented via patients logs and heart rate monitor. - the effect of the training will be evaluated one year after the transplantation

NCT ID: NCT06367205 Recruiting - Clinical trials for End Stage Renal Disease

Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.

NCT ID: NCT06365437 Recruiting - Clinical trials for Kidney Transplantation

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Start date: June 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.

NCT ID: NCT06348446 Recruiting - Clinical trials for Kidney Transplant Rejection

Tacrolimus Exposure in Kidney Transplantation

Start date: February 1, 2022
Phase:
Study type: Observational

Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation.

NCT ID: NCT06314230 Recruiting - Clinical trials for Kidney Transplant; Complications

Australian Genomics Of Chronic Allograft Dysfunction Study

AUSCAD
Start date: April 26, 2012
Phase:
Study type: Observational [Patient Registry]

The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.

NCT ID: NCT06260579 Recruiting - Physical Activity Clinical Trials

Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity

PHOENIX-Kidney
Start date: November 14, 2022
Phase: N/A
Study type: Interventional

This multicentre two-phased RCT aims to evaluate implementation potential, cost-effectiveness, effectiveness, and the role of exercise intensity of a home-based exercise and physical activity intervention to improve de novo kidney transplant recipients' physical fitness, cardiovascular health, gut microbiome characteristics, and health-related quality of life. The first phase of this study comprehends a six-month exercise training intervention. Patients will be randomized into (i) a sham intervention consisting of low-intensity balance and stretching exercises (LIT), (ii) a moderate-intensity aerobic and strength training intervention (MIT), or (iii) a moderate- and high-intensity aerobic and strength training intervention (MHIT). The second phase of this study comprehends a physical activity maintenance intervention provided to MIT and MHIT but not LIT. A total of 147 de novo kidney transplant recipients will be recruited from two independent Belgian transplant centres i.e. UZ Leuven and UZ Ghent.

NCT ID: NCT06243289 Recruiting - Clinical trials for Kidney Transplant Rejection

Improving KIdney Transplantation With Cellular Therapy Study

i-KITCaT
Start date: September 19, 2023
Phase:
Study type: Observational

The i-KITCaT study aims to harness cellular therapies to favourably alter the immunological response to in AKI in transplantation. Kidney transplantation offers the best survival and quality of life outcomes for patients with end-stage kidney disease but requires life-long immunosuppression. Efforts to increase the donor organ pool means accepting kidneys which have been subjected to medical and surgical factors culminating in acute kidney injury (AKI). There is no treatment to modify the maladaptive injury process following an AKI insult, and this subjects the new kidney to increased risk of needing dialysis in the first 7 days of transplantation, rejection, and shortened transplant survival. Tolerogenic dendritic cells (TolDC) are currently used in phase I/II clinical trials and are safe for patients receiving a kidney transplant from the same donor as these cells. These trials focus on transplant tolerance, but we will re-purpose TolDCs to favorably alter the disease course following AKI and limit injury following transplantation. Furthermore, if the patient's own cells (rather than from a third-party donor) can be used, this avoids supply limitations and potential sensitization risk. We will compare the functional characteristics of TolDC generated from control (healthy) and kidney disease (chronic kidney disease (CKD), dialysis and transplantation).

NCT ID: NCT06234410 Recruiting - Clinical trials for Cardiovascular Diseases

Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation

CRAFT-CTCA
Start date: January 24, 2024
Phase:
Study type: Observational

Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure. Kidney transplantation reduces cardiovascular risk but cardiovascular disease remains the commonest cause of death in patients following transplantation. Current strategies to assess patient's cardiovascular risk prior to kidney transplantation do not identify those at highest risk and do not improve outcomes. This study will use a heart scan known as computed tomography coronary angiography (CTCA) to see whether this scan can identify patients at highest risk of future cardiovascular disease prior to transplantation. Studies have shown it is able to do this in patients with normal kidney function. The aim of this study is to develop CTCA as an effective tool to risk stratify patients prior to kidney transplantation.